A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis

Blood

Volumn 107, Issue 11, 2006, Pages 4300-4307

  Nakamura, Takanori ^a   Miyakawa, Yoshitaka ^b   Miyamura, Atsushi ^b   Yamane, Akiko ^b   Suzuki, Hidenori ^b   Ito, Mamoru ^b   Ohnishi, Yasuyuki ^b   Ishiwata, Norihisa ^b   Ikeda, Yasuo ^b   Tsuruzoe, Nobutomo ^b  

^a NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKINE RECEPTOR AGONIST; HISTIDINE; NIP 004; PROTEIN C MPL; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL MEMBRANE; CELL TRANSPLANTATION; CIRCULATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; HAMSTER; HUMAN; HUMAN CELL; IN VIVO CULTURE; MEGAKARYOBLAST; MEGAKARYOPOIESIS; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; STIMULUS RESPONSE; THROMBOCYTE; THROMBOCYTOPOIESIS; UMBILICAL CORD BLOOD; XENOGRAFT;

EID: 33744456732     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4433     Document Type: Article

References (36)

1. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-538.
2. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-568.
3. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568-571.
4. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571-574.
5. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-1124.
6. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002;21:3359-3367.
7. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457-3469.
8. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.
9. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175-3182.
10. Jenkins J, Nicholl R, Williams D, et al. An oral, non-petide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects [abstract]. Blood. 2004;104:797a. Abstract 2916.
11. Jackson CW. Cholinesterase as a possible marker for early cells of the megakaryocytic series. Blood. 1973;42:413-421.
12. Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997;89:3148-3154.
13. Suzuki H, Yamazaki H, Tanoue K. Immunocytochemical studies on co-localization of alpha-granule membrane alphaIIbbeta3 integrin and intragranular fibrinogen of human platelets and their cell-surface expression during the thrombin-induced release reaction. J Electron Microsc (Tokyo). 2003;52:183-195.
14. Hagberg IA, Lyberg T. Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies. Platelets. 2000;11:137-150.
15. Guideline for animal experimentation. [in japanese]. Exp Anim. 1987;36:285-288.
16. Komatsu N, Kunitama M, Yamada M, et al. Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO. Blood. 1996;87:4552-4560.
17. Komatsu N, Nakauchi H, Miwa A, et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 1991;51:341-348.
18. Takatoku M, Kametaka M, Shimizu R, Miura Y, Komatsu N. Identification of functional domains of the human thrombopoietin receptor required for growth and differentiation of megakaryocytic cells. J Biol Chem. 1997;272:7259-7263.
19. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood. 1993;82:456-464.
20. Vainchenker W, Deschamps JF, Bastin JM, et al. Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood. 1982;59:514-521.
21. van den Oudenrijn S, von dem Borne AE, de Haas M. Differences in megakaryocyte expansion potential between CD34(+) stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp Hematol. 2000;28:1054-1061.
22. Kimura T, Kaburaki H, Tsujino T, Ikeda Y, Kato H, Watanabe Y. A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl. FEBS Lett. 1998;428:250-254.
23. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem. 2002;45:3576-3578.
24. Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem. 2001;44:3730-3745.
25. Inagaki K, Oda T, Naka Y, Shinkai H, Komatsu N, Iwamura H. Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood. 2004;104:58-64.
26. Sakai R, Nakamura T, Nishino T, et al. Xanthocillins as thrombopoietin mimetic small molecules. Bioorg Med Chem. 2005;13:6388-6393.
27. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85-93.
28. Erickson-Miller CL, Delorme E, Iskander M, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist [abstract]. Blood. 2004;104:795a.
29. Onishi M, Mui AL, Morikawa Y, et al. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Blood. 1996;88:1399-1406.
30. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198-4200.
31. Jenkins BJ, D'Andrea R, Gonda TJ. Activating point mutations in the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors suggest the involvement of beta subunit dimerization and cell type-specific molecules in signalling. EMBO J. 1995;14:4276-4287.
32. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001;98:4379-4384.
33. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12:814-821.
34. Perez LE, Rinder HM, Wang C, Tracey JB, Maun N, Krause DS. Xenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production. Blood. 2001;97:1635-1643.
35. Perez LE, Alpdogan O, Shieh JH, et al. Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp Hematol. 2004;32:300-307.
36. Angelopoulou MK, Rinder H, Wang C, Burtness B, Cooper DL, Krause DS. A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftment. Transfusion. 2004;44:555-566.